Gilead Sciences, Inc. (GILD)

Gilead Sciences' stock price has been impacted by several events in the past six months. The stock experienced a strong multi-year run but had an 11% pullback from its 52-week high due to a broad market selloff. Gilead announced its third-quarter and fourth-quarter 2025 results, with revenue increases driven by HIV and Liver Disease product sales. Gilead announced acquisitions of Arcellx, Ouro Medicines and Tubulis, and a collaboration with Galapagos NV.

The provided search results do not explicitly detail demand seasonality for Gilead Sciences, Inc.'s products and services. However, financial reports indicate sales trends for different product categories over quarters and years. Veklury sales decreased significantly due to lower rates of COVID-19-related hospitalizations, while HIV and Liver Disease product sales have shown consistent growth. It is not possible to definitively describe a general demand seasonality across Gilead's entire product portfolio.

Gilead Sciences, Inc. is an American biopharmaceutical company focused on researching, developing, and commercializing medicines to prevent and treat life-threatening diseases. The company has a strong portfolio in HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, and has strategically expanded into oncology and hematology. Major products include HIV and antiviral therapies, liver disease treatments, oncology and hematology therapies, and other treatments for conditions like fungal infections and pulmonary hypertension.

Gilead Sciences has a significant global presence, operating in over 35 countries worldwide. Its headquarters are in Foster City, California, USA. Key locations include sites in the United States, Canada, Mexico, Europe, Asia, South America, Africa, Australia, and the Middle East. Revenue performance shows U.S. revenue recovering and growing through 2025, while international asset turnover has consistently increased.

Gilead Sciences has built a reputation as a biopharmaceutical company focused on advancing medicines for life-threatening diseases, particularly in antiviral therapies. The company's ongoing research and development efforts, coupled with strategic acquisitions in oncology and autoimmune diseases, demonstrate a commitment to innovation and addressing unmet medical needs. The successful launch of new therapies and the continued growth of key products contribute positively to its standing in the industry.

Gilead Sciences, Inc. is a publicly traded company with ownership distributed among shareholders. Institutional investors hold a significant portion of the company's stock, ranging from 73.00% to 83.67%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Fmr Llc. Individual investors also hold shares, and insiders own a small percentage of the stock.